268 related articles for article (PubMed ID: 31375867)
41. How significant is detection of ductal carcinoma in situ in a breast screening programme?
Kessar P; Perry N; Vinnicombe SJ; Hussain HK; Carpenter R; Wells CA
Clin Radiol; 2002 Sep; 57(9):807-14. PubMed ID: 12384106
[TBL] [Abstract][Full Text] [Related]
42. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma
Glencer AC; Miller PN; Greenwood H; Maldonado Rodas CK; Freimanis R; Basu A; Mukhtar RA; Brabham C; Kim P; Hwang ES; Rosenbluth JM; Hirst GL; Campbell MJ; Borowsky AD; Esserman LJ
Cancer Res Commun; 2022 Dec; 2(12):1579-1589. PubMed ID: 36970720
[TBL] [Abstract][Full Text] [Related]
43. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.
Maxwell AJ; Clements K; Hilton B; Dodwell DJ; Evans A; Kearins O; Pinder SE; Thomas J; Wallis MG; Thompson AM;
Eur J Surg Oncol; 2018 Apr; 44(4):429-435. PubMed ID: 29398324
[TBL] [Abstract][Full Text] [Related]
44. Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma.
Lamb LR; Lehman CD; Oseni TO; Bahl M
Acad Radiol; 2020 Oct; 27(10):1394-1399. PubMed ID: 31699638
[TBL] [Abstract][Full Text] [Related]
45. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.
Yoon HJ; Kim Y; Kim BS
Eur Radiol; 2015 Dec; 25(12):3648-58. PubMed ID: 26063655
[TBL] [Abstract][Full Text] [Related]
46. The Role of High-Resolution Magic Angle Spinning 1H Nuclear Magnetic Resonance Spectroscopy for Predicting the Invasive Component in Patients with Ductal Carcinoma In Situ Diagnosed on Preoperative Biopsy.
Chae EY; Shin HJ; Kim S; Baek HM; Yoon D; Kim S; Shim YE; Kim HH; Cha JH; Choi WJ; Lee JH; Shin JH; Lee HJ; Gong G
PLoS One; 2016; 11(8):e0161038. PubMed ID: 27560937
[TBL] [Abstract][Full Text] [Related]
47. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
[TBL] [Abstract][Full Text] [Related]
48. Predictive significance of breast-specific gamma imaging for upstaging core-needle biopsy-detected ductal carcinoma in situ to invasive cancer.
Yoo J; Kim BS; Yoon HJ
Ann Nucl Med; 2018 Jun; 32(5):328-336. PubMed ID: 29556944
[TBL] [Abstract][Full Text] [Related]
49. Overdiagnosis in breast imaging.
Evans A; Vinnicombe S
Breast; 2017 Feb; 31():270-273. PubMed ID: 28029492
[TBL] [Abstract][Full Text] [Related]
50. Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin).
Alexander M; Beyda J; Nayak A; Jaffer S
Arch Pathol Lab Med; 2019 Jan; 143(1):99-104. PubMed ID: 29932858
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients.
Moon HJ; Kim EK; Kim MJ; Yoon JH; Park VY
Ultrasound Med Biol; 2019 Jan; 45(1):68-77. PubMed ID: 30322671
[TBL] [Abstract][Full Text] [Related]
52. High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management.
Michaels AY; Ginter PS; Dodelzon K; Naunheim MR; Abbey GN
AJR Am J Roentgenol; 2021 Mar; 216(3):622-632. PubMed ID: 33439046
[No Abstract] [Full Text] [Related]
53. Ductal carcinoma in situ: treatment or active surveillance?
Kuerer HM
Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
[TBL] [Abstract][Full Text] [Related]
54. Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma.
Lamb LR; Kim G; Oseni TO; Bahl M
Acad Radiol; 2021 Mar; 28(3):e71-e76. PubMed ID: 32222328
[TBL] [Abstract][Full Text] [Related]
55. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
Tsang WY; Chan JK
Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
[TBL] [Abstract][Full Text] [Related]
56. Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK; Almekinders MM; Mulder C; Bhattacharjee P; Collyar D; Thompson AM; Jonkers J; Lips EH; van Rheenen J; Hwang ES; Nik-Zainal S; Navin NE; Wesseling J;
Nat Rev Cancer; 2022 Dec; 22(12):663-678. PubMed ID: 36261705
[TBL] [Abstract][Full Text] [Related]
57. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
58. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.
van la Parra RF; Ernst MF; Barneveld PC; Broekman JM; Rutten MJ; Bosscha K
Eur J Surg Oncol; 2008 Jun; 34(6):631-5. PubMed ID: 17851019
[TBL] [Abstract][Full Text] [Related]
59. Lesion size is a major determinant of the mammographic features of ductal carcinoma in situ: findings from the Sloane project.
Evans A; Clements K; Maxwell A; Bishop H; Hanby A; Lawrence G; Pinder SE;
Clin Radiol; 2010 Mar; 65(3):181-4. PubMed ID: 20152272
[TBL] [Abstract][Full Text] [Related]
60. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
